This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xu, J. Articles by Wu, G. S. Search for Related Content PubMed PubMed Citation Articles by Xu, J. Articles by Wu, G. S.

Evidence that Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Induction by 5-Aza-2'-Deoxycytidine Sensitizes Human Breast Cancer Cells to Adriamycin

Program in Molecular Biology and Genetics, Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan

Requests for reprints: Gen Sheng Wu, Program in Molecular Biology and Human Genetics, Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201. Phone: 313-833-0715, ext. 2328; Fax: 313-831-7518; E-mail: wug{at}karmanos.org.

The DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) inhibits DNA methyltransferase activity and sensitizes cancer cells to chemotherapy, but the mechanisms of its sensitization are not fully understood. Here, we show that 5-aza-CdR induces tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) in the human breast cancer MDA-231 cells. Induction of TRAIL by 5-aza-CdR correlated with inactivation of Akt. Furthermore, we show that overexpression of the active form of Akt by adenovirus infection or inhibition of the Akt downstream target glycogen synthase kinase 3 by its pharmacologic inhibitors abolishes TRAIL induction by 5-aza-CdR. Importantly, we show that the combined treatment of breast cancer cells with 5-aza-CdR and Adriamycin significantly increases apoptotic cell death compared with the treatment with either agent alone. Moreover, the combined treatment activated both death receptor and mitochondrial apoptotic pathways, whereas Adriamycin alone activated only the mitochondrial pathway while 5-aza-CdR failed to activate either. More importantly, down-regulation of TRAIL by small interference RNA silencing decreased 5-aza-CdR–mediated Adriamycin-induced caspase activation and apoptosis, thus conferring Adriamycin resistance. Taken together, our results suggest that induction of TRAIL by 5-aza-CdR is critical for enhancing chemosensitivity of breast cancer cells to Adriamycin. [Cancer Res 2007;67(3):1203–11]

This article has been cited by other articles:

				J. Xu, J.-Y. Zhou, W.-Z. Wei, S. Philipsen, and G. S. Wu Sp1-Mediated TRAIL Induction in Chemosensitization Cancer Res., August 15, 2008; 68(16): 6718 - 6726. [Abstract] [Full Text] [PDF]

				J. Wang, J.-Y. Zhou, and G. S. Wu ERK-Dependent MKP-1 Mediated Cisplatin Resistance in Human Ovarian Cancer Cells Cancer Res., December 15, 2007; 67(24): 11933 - 11941. [Abstract] [Full Text] [PDF]

				J. B. Stevens, G. Liu, S. W. Bremer, K. J. Ye, W. Xu, J. Xu, Y. Sun, G. S. Wu, S. Savasan, S. A. Krawetz, et al. Mitotic Cell Death by Chromosome Fragmentation Cancer Res., August 15, 2007; 67(16): 7686 - 7694. [Abstract] [Full Text] [PDF]